Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase 2 2Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Primary Myelofibrosis 6Myeloproliferative Disorders 6Polycythemia Vera 5Pancreatic Neoplasms 2Neoplasms 2Hematologic Diseases 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Lymphoma, Follicular 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1Bone Marrow Diseases 1

Interventions

Gemcitabine 74Fluorouracil 31Oxaliplatin 21Leucovorin 21130-nm albumin-bound paclitaxel 17Capecitabine 14Irinotecan 12Albumin-Bound Paclitaxel 10irinotecan sucrosofate 8Radiotherapy 6Taxes 5Erlotinib Hydrochloride 5folfirinox 4rubitecan 3Surgical Procedures, Operative 3Specimen Handling 3Pancreaticojejunostomy 3Neoadjuvant Therapy 3Drug Therapy 3Cisplatin 3Chemotherapy, Adjuvant 3ruxolitinib 2masitinib 2dehydroftorafur 2Saline Solution 2S 1 (combination) 2Paclitaxel 2GV1001 peptide 2Fentanyl 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Neoplasms × ruxolitinib × Clear all
NCT02117479 2019-03-26

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Incyte Corporation

Phase 3 Terminated
321 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02119663 2018-02-13

A Study of Ruxolitinib in Pancreatic Cancer Patients

Incyte Corporation

Phase 3 Terminated
86 enrolled 12 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡